NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer

Taofei Zeng; Guanglei Chen; Xinbo Qiao; Hui Chen; Lisha Sun; Qingtian Ma; Na Li; Junqi Wang; Chaoliu Dai; Feng Xu

doi:10.3389/fphar.2022.823140

NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer

Front Pharmacol. 2022 Apr 1:13:823140. doi: 10.3389/fphar.2022.823140. eCollection 2022.

Authors

Taofei Zeng¹, Guanglei Chen², Xinbo Qiao², Hui Chen³, Lisha Sun², Qingtian Ma², Na Li^{4

5}, Junqi Wang¹, Chaoliu Dai¹, Feng Xu¹

Affiliations

¹ Department of General Surgery, Hepatobiliary and Splenic Surgery Ward, Shengjing Hospital of China Medical University, Shenyang, China.
² Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
³ Department of General Surgery, Pancreatic and Thyroid Surgery Ward, Shengjing Hospital of China Medical University, Shenyang, China.
⁴ Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
⁵ Department of Pediatrics, The Second Affiliated Hospital of DaLian Medical University, Dalian, China.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) has gradually emerged as the most prevalent cause of chronic liver diseases. However, specific changes during the progression of NAFLD from non-fibrosis to advanced fibrosis and then hepatocellular carcinoma (HCC) are unresolved. Here, we firstly identify the key gene linking NAFLD fibrosis and HCC through analysis and experimental verification. Methods: Two GEO datasets (GSE89632, GSE49541) were performed for identifying differentially expressed genes (DEGs) associated with NAFLD progression from non-fibrosis to early fibrosis and eventually to advanced fibrosis. Subsequently, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis, protein-protein interaction (PPI) network were integrated to explore the potential function of the DEGs and hub genes. The expression of NUSAP1 was confirmed in vivo and in vitro NAFLD models at mRNA and protein level. Then, cell proliferation and migration under high fat conditions were verified by cell counting kit-8 (CCK-8) and wound-healing assays. The lipid content was measured with Oil Red O staining. Finally, the analysis of clinical survival curves was performed to reveal the prognostic value of the crucial genes among HCC patients via the online web-tool GEPIA2 and KM plotter. Results: 5510 DEGs associated with non-fibrosis NAFLD, 3913 DEGs about NAFLD fibrosis, and 739 DEGs related to NAFLD progression from mild fibrosis to advanced fibrosis were identified. Then, a total of 112 common DEGs were found. The result of enrichment analyses suggested that common DEGs were strongly associated with the glucocorticoid receptor pathway, regulation of transmembrane transporter activity, peroxisome, and proteoglycan biosynthetic process. Six genes, including KIAA0101, NUSAP1, UHRF1, RAD51AP1, KIF22, and ZWINT, were identified as crucial candidate genes via the PPI network. The expression of NUSAP1 was validated highly expressed in vitro and vivo NAFLD models at mRNA and protein level. NUSAP1 silence could inhibit the ability of cell proliferation, migration and lipid accumulation in vitro. Finally, we also found that NUSAP1 was significantly up-regulated at transcriptional and protein levels, and associated with poor survival and advanced tumor stage among HCC patients. Conclusion: NUSAP1 may be a potential therapeutic target for preventing NAFLD progression to liver cancer.

Keywords: bioinformatics analysis; drug targets; hepatocellular carcinoma; liver fibrosis; non-alcoholic fatty liver disease.